| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1090678503 |
| P356 | DOI | 10.1186/S40661-017-0047-8 |
| P932 | PMC publication ID | 5512733 |
| P698 | PubMed publication ID | 28725449 |
| P50 | author | Bradley J. Monk | Q107013145 |
| P2093 | author name string | Brett Miles | |
| Howard P Safran | |||
| P2860 | cites work | Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States | Q22306233 |
| Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma | Q26782499 | ||
| Therapy of human papillomavirus-related disease | Q27007473 | ||
| FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) | Q28283721 | ||
| Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 | ||
| Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
| Global burden of cancers attributable to infections in 2008: a review and synthetic analysis | Q29620303 | ||
| Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study | Q30434661 | ||
| Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base (NCDB) analysis | Q30930781 | ||
| Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base | Q31057384 | ||
| Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer | Q33427796 | ||
| Improved survival with bevacizumab in advanced cervical cancer | Q33566222 | ||
| A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. | Q33834057 | ||
| Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments | Q34021545 | ||
| Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers | Q34022316 | ||
| Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). | Q34332463 | ||
| Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions | Q34415650 | ||
| Human papillomavirus infection: biology, epidemiology, and prevention | Q34452405 | ||
| Biological activities and molecular targets of the human papillomavirus E7 oncoprotein | Q34468787 | ||
| Persistence of human papillomavirus infection: keys to malignant progression | Q34690139 | ||
| Combined-modality therapy of locally advanced cervical cancer | Q35125954 | ||
| Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. | Q35563824 | ||
| Lm-LLO-Based Immunotherapies and HPV-Associated Disease | Q35838127 | ||
| Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review | Q35886444 | ||
| Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma | Q36405555 | ||
| Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. | Q36483341 | ||
| The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system | Q36541450 | ||
| Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum | Q36826250 | ||
| Innate and adaptive immune responses to Listeria monocytogenes: a short overview. | Q36919046 | ||
| Papillomavirus E6 and E7 proteins and their cellular targets | Q36992007 | ||
| Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline | Q37223983 | ||
| Papillomavirus E6 proteins | Q37350446 | ||
| Human papillomavirus oncoproteins: pathways to transformation | Q37769103 | ||
| Regulation of Listeria virulence: PrfA master and commander | Q37851228 | ||
| Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? | Q37943790 | ||
| Global burden of human papillomavirus and related diseases. | Q38064060 | ||
| Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma. | Q38807472 | ||
| Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes | Q38808706 | ||
| Integrated genomic characterization of oesophageal carcinoma | Q39041152 | ||
| Global burden of cancers attributable to infections in 2012: a synthetic analysis. | Q39360739 | ||
| Minimally invasive therapy of cervical intraepithelial neoplasia for fertility preservation | Q40009834 | ||
| Development of a Listeria monocytogenes based vaccine against prostate cancer. | Q40013300 | ||
| The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix | Q40391633 | ||
| Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients | Q40570530 | ||
| Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices | Q41156019 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer | Q43596600 | ||
| Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment | Q43915996 | ||
| Evolving immunosuppressive microenvironment during human cervical carcinogenesis | Q44628163 | ||
| Beyond cervical cancer: burden of other HPV-related cancers among men and women | Q44737179 | ||
| Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia | Q45142471 | ||
| A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. | Q46564278 | ||
| A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals | Q46732942 | ||
| Splenic CD8α⁺ dendritic cells undergo rapid programming by cytosolic bacteria and inflammation to induce protective CD8⁺ T-cell memory. | Q51013895 | ||
| Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. | Q51261289 | ||
| Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. | Q51820508 | ||
| The epidermal growth factor receptors as biological targets in penile cancer. | Q55069363 | ||
| Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine | Q61626178 | ||
| Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity | Q61626183 | ||
| A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours | Q71803282 | ||
| Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study | Q80396730 | ||
| P304 | page(s) | 10 | |
| P577 | publication date | 2017-07-14 | |
| P1433 | published in | Gynecologic oncology research and practice | Q27727212 |
| P1476 | title | Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001. | |
| P478 | volume | 4 |
| Q97592235 | A listeriolysin O subunit vaccine is protective against Listeria monocytogenes |
| Q91637388 | Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer |
| Q49797507 | Rational Design for Cervical Cancer Therapeutics: Cellular and Non-Cellular Based Strategies on the Horizon for Recurrent, Metastatic or Refractory Cervical Cancer. |
| Q54217605 | Targeting Head and Neck Cancer by Vaccination. |
| Q90385101 | The current status of immunotherapy for cervical cancer |
| Q50115667 | Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. |
| Q57149794 | Therapeutic human papillomavirus vaccines in head and neck cancer: A systematic review of current clinical trials |
| Q56893452 | Trial watch: DNA-based vaccines for oncological indications |
| Q58599910 | Tumour-targeting bacteria engineered to fight cancer |
| Q56898750 | White paper on microbial anti-cancer therapy and prevention |
Search more.